Search

For the first time in > 30 years of routine sampling under the Arctic Monitoring and Assessment Program, a parasite was found in the liver of ringed seals (Phoca hispida) collected near Qaanaaq (Thule), Northwest Greenland, in 2008 and 2014. Concerns regarding changes to parasite occurrence, possibly related to climate change and bioaccumulation of immunomodulating anthropogenic pollutants, spurred further investigations into parasite characterization, and implications for wildlife health and seal hunters. Microscopic, molecular, and morphometric analyses are presented herein. Of 40 seals, 6 (15%) were infected, and 5 of 6 of these seals had severe infections. The parasite was identified morphologically as Orthosplanchnus arcticus Odhner, 1905 (Trematoda; Digenea: Brachycladiidae). Macro- and microscopic pathologic study indicated mild-to-severe biliary hyperplasia associated, stasis associated, and fibrosis associated with trematode infections. Molecular analysis of the trematode confirmed its classification within the Brachycladiidae using sequencing and comparing Internal Transcribed Spacer-1, mitochondrial-NADH Dehydrogenase 3, 18S ribosomal DNA, and Cyclooxygenase-1 regions. This is the first ever report of O. arcticus in ringed seals from Qaanaaq and is one of the most northern records of this parasite. We found significant liver pathology in severely infected seals, but its effects on health of seals in this population are unknown. Host-specificity and the lifecycle of O. arcticus are unknown, but transmission may involve subsistence and commercially harvested Arctic fish species. Further work is needed to answer these questions. Surveying parasites in Arctic wildlife is important in order to assess potential effects on wildlife and human health (i.e., zoonoses). [ABSTRACT FROM AUTHOR]

Aims: To investigate the relationship between arterial stiffness and insulin treatment mode [continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI)] in type 1 diabetes patients. Methods: Cross-sectional study, from 2009 to 2011, including 601 Caucasian type 1 diabetes patients, 58 and 543 treated with CSII and MDI, respectively. Arterial stiffness was measured as pulse wave velocity (PWV) (SphygmoCor, AtCor Medical). Adjustment included gender, age, diabetes duration, HbA, heart rate, mean arterial pressure, P-creatinine, urinary albumin excretion rate (UAER), smoking, total daily insulin dose, antihypertensive treatment, previous cardiovascular disease (CVD), total cholesterol and statin treatment. Albuminuria was UAER ≥30 mg/24-h, and CVD included myocardial infarction, revascularization, peripheral arterial disease and stroke. Results: CSII- versus MDI-treated patients were 48 versus 57 % men, 51 ± 11 versus 54 ± 13 years old (mean ± SD), had 33 ± 12 versus 32 ± 16 years diabetes duration and HbA 7.8 ± 0.9 % (62 ± 10 mmol/mol) versus 8.0 ± 1.2 % (64 ± 13 mmol/mol) ( P ≥ 0.08 for all). PWV was lower in CSII- versus MDI-treated patients (9.3 ± 2.8 vs. 10.4 ± 3.4 m/s; P = 0.016). In fully adjusted analysis, CSII treatment was significantly ( P = 0.038) associated with lower PWV, whereas HbA-level was not ( P = 0.93). Conclusions: In type 1 diabetes patients, CSII treatment was associated with lower arterial stiffness independent of other risk factors, while HbA was not. Although glucose variability was not assessed, our results suggest that glucose variability and not HbA-level affect arterial stiffness. This needs confirmation in randomised prospective studies. [ABSTRACT FROM AUTHOR]

Presents several studies on kidney dialysis. Analysis of the effectiveness of catheter-restricted filling with gentamicin and citrate in preventing catheter-related infections in hemodialysis patients; Aspects of hepatitis C infection in patient with end-stage renal disease; Effects of comorbid conditions on the outcomes of patients undergoing peritoneal dialysis; Prevalence of gastrointestinal complaints; Risk factors for hip fracture in hemodialysis patients.